Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies
about
A survey of renal impairment pharmacokinetic studies for new oncology drug approvals in the USA from 2010 to early 2015: a focus on development strategies and future directionsHarmonization of Renal Function Assessment Is Needed During Early Clinical Development of Oncology Drugs.Dose adjustment of cisplatin, etoposide, and ifosfamide according to kidney function: a retrospective analysis and implications for medication safety.The renal safety and efficacy of combined gemcitabine plus cisplatin and gemcitabine plus carboplatin chemotherapy in Chinese patients with a solitary kidney after nephroureterectomy.Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?
P2860
Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 September 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effect of Renal Dysfunction on ...... d Single-Agent Phase I Studies
@en
Effect of Renal Dysfunction on ...... Single-Agent Phase I Studies.
@nl
type
label
Effect of Renal Dysfunction on ...... d Single-Agent Phase I Studies
@en
Effect of Renal Dysfunction on ...... Single-Agent Phase I Studies.
@nl
prefLabel
Effect of Renal Dysfunction on ...... d Single-Agent Phase I Studies
@en
Effect of Renal Dysfunction on ...... Single-Agent Phase I Studies.
@nl
P2093
P2860
P356
P1476
Effect of Renal Dysfunction on ...... d Single-Agent Phase I Studies
@en
P2093
Diana Viluh
Hussein Tawbi
Indrani Chatterjee
Matthew Rinker
S Percy Ivy
Selina L Chow
P2860
P304
P356
10.1200/JCO.2014.59.7302
P407
P50
P577
2015-09-21T00:00:00Z